全文获取类型
收费全文 | 1139篇 |
免费 | 142篇 |
国内免费 | 28篇 |
专业分类
化学 | 1196篇 |
晶体学 | 1篇 |
力学 | 14篇 |
综合类 | 17篇 |
数学 | 56篇 |
物理学 | 25篇 |
出版年
2024年 | 6篇 |
2023年 | 15篇 |
2022年 | 90篇 |
2021年 | 47篇 |
2020年 | 97篇 |
2019年 | 99篇 |
2018年 | 76篇 |
2017年 | 80篇 |
2016年 | 67篇 |
2015年 | 79篇 |
2014年 | 65篇 |
2013年 | 108篇 |
2012年 | 77篇 |
2011年 | 52篇 |
2010年 | 47篇 |
2009年 | 46篇 |
2008年 | 54篇 |
2007年 | 45篇 |
2006年 | 34篇 |
2005年 | 25篇 |
2004年 | 15篇 |
2003年 | 24篇 |
2002年 | 12篇 |
2001年 | 7篇 |
2000年 | 6篇 |
1999年 | 7篇 |
1998年 | 8篇 |
1997年 | 1篇 |
1996年 | 8篇 |
1995年 | 2篇 |
1994年 | 3篇 |
1993年 | 1篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
排序方式: 共有1309条查询结果,搜索用时 15 毫秒
111.
112.
A rapid, selective, and sensitive liquid chromatography–tandem mass spectrometry method was developed and validated for the simultaneous determination of unbound sunitinib and its active metabolite N‐desethyl sunitinib in plasma. Plasma and post‐dialysis buffer samples were extracted using a liquid–liquid extraction procedure with acetonitrile–n‐butylchloride (1:4, v/v). Chromatographic separation was achieved on a Waters X‐Terra® MS RP18 column with a mobile phase consisting of acetonitrile and water (60:40, v/v) containing formic acid (0.1%, v/v) using an isocratic run, at a flow‐rate of 0.2 mL/min. Analytes were detected by electrospray tandem mass spectrometry in the selective reaction monitoring mode. Linear calibration curves were generated over the ranges 0.1–100 and 0.02–5 ng/mL for sunitinib and 0.2–200 and 0.04–10 ng/mL for N‐desethyl sunitinib in plasma and in phosphate‐buffered solution, respectively. The values for both within‐day and between‐day precision and accuracy were well within the generally accepted criteria for analytical methods. The analytical range was sufficient to determine the unbound and total concentrations of both analytes. The method was applied for measurement unbound concentrations in addition to total concentrations of sunitinib and its metabolite in plasma of a cancer patient receiving 50 mg daily dose. Copyright © 2012 John Wiley & Sons, Ltd. 相似文献
113.
A liquid chromatographic-mass spectrometry (LC/MS) assay method was developed for the determination of amiodarone and desethylamiodarone in rat specimens. Analytes were extracted using liquid-liquid extraction in hexane. The LC/MS system consisted of a Waters Micromass ZQtrade mark 4000 spectrometer with an autosampler and pump. A C(18) 3.5 microm (2.1 x 50 mm) column heated to 45 degrees C was used for separation. The mobile phase consisted of methanol and 0.2% aqueous formic acid pumped at 0.2 mL/min as a linear gradient. Components eluted within 12 min. The concentrations of ethopropazine (internal standard), desethylamiodarone and amiodarone were monitored for m/z of 313.10, combination of 546.9 and 617.73, and 645.83, respectively. In plasma (0.1 mL), linearity was achieved between the peak area ratios and concentrations over the range of 2.5-1000 ng/mL for both amiodarone and desethylamiodarone (r(2) > 0.999). The intraday and interday CV were equal or less than 18%, and mean error was <12%. Similarly, in homogenates containing 0.1 g of rat tissue, linearity was observed in standards ranging from 5 to 5000 ng/g. The method was successfully used to measure tissue and plasma concentrations of drug. The validated lower limit of quantitation was 2.5 ng/mL for drug and metabolite, based on 0.1 mL of plasma. 相似文献
114.
A fast and sensitive high performance liquid chromatography method for quantitative determination of rosiglitazone in human plasma has been developed. The extraction from plasma was performed using solid-phase extraction (SPE) on C4 silica (100 mg) disposable extraction cartridges (DEC). The separation of rosiglitazone and two metabolites was achieved on a Phenomenex® Synergi 4 µm MAX-RP (150 × 4.6 mm) column, protected by a guard column. The mobile phase was 0.01 M ammonium acetate, pH 7.0 - acetonitrile (65:35, v/v). (3S)-3-OH-quinidine was used as internal standard. The analytes were detected using fluorescence detection. The method was validated. The limit of quantitation was 1 ng mL−1 and the detection limit was 0.25 ng mL−1 for rosiglitazone in human plasma. The recovery was 90% for rosiglitazone. Linearity was observed over a range of 1-1000 ng mL−1 (r2=0.9959). The intra- and inter-day precision (C.V.) did not exceed 8.7 %. Applicability of the method was demonstrated by a clinical pharmacokinetic study. A healthy volunteer received in two separate phases 4 mg and 8 mg rosiglitazone maleate as a single oral dose. Plasma concentrations were measured for 24 h in both phases. 相似文献
115.
高分子材料合成实验是高分子专业的核心实验课程之一,如何建立实验课程与理论课程的有效衔接,加深学生对所学知识点的深入理解和活学活用,是本课程的主要目标。为此,笔者和教学团队提出:在同一个实验中改变某个实验变量,在教学班中引入对比实验,通过这些改变引起的不同实验现象和由此产生的材料性能的迥然差异,引导学生从现象出发,联系理论课堂知识进行深入分析。这种尝试有效改变了以往实验教学中所有教学班千篇一律的操作和几乎完全相同的实验现象与结果,有效激发了学生的主动性,提高了其分析问题、解决问题的能力。2年的实验教学反馈表明,“对比实验的引入”和“现象驱动的知识挖掘”帮助学生有效巩固了理论课堂的知识点,做到了活学活用。 相似文献
116.
Ziritaxestat is a first-in-class autotoxin inhibitor. The purpose of this study was to develop a liquid chromatography/electrospray ionization tandem mass spectrometric (LC–MS/MS) method for the determination of ziritaxestat in rat plasma. The plasma sample was deproteinated using acetonitrile and then separated on an Acquity BEH C18 column with water containing 0.1% formic acid and acetonitrile as mobile phase, which was delivered at 0.4 ml/min. Ziritaxestat and the internal standard (crizotinib) were quantitatively monitored with precursor-to-product transitions of m/z 589.3 > 262.2 and m/z 450.1 > 260.2, respectively. The total running time was 2.5 min. The method showed excellent linearity over the concentration range 0.5–2000 ng/ml, with correlation coefficient >0.9987. The extraction recovery was >82.09% and the matrix effect was not significant. Inter- and intra-day precisions (RSD) were <11.20% and accuracies were in the range of −8.50–7.45%. Ziritaxestat was demonstrated to be stable in rat plasma under the tested conditions. The validated LC–MS/MS method was successfully applied to study the pharmacokinetic profiles of ziritaxestat in rat plasma after intravenous and oral administration. Pharmacokinetic results demonstrated that ziritaxestat displayed a short half-life (~3 h) and low bioavailability (20.52%). 相似文献
117.
Dajana Vuckovic Inés de Lannoy Brad Gien Yingbo Yang Florin Marcel Musteata Robert Shirey Leonard Sidisky Janusz Pawliszyn 《Journal of chromatography. A》2011,1218(21):3367-3375
The use of solid-phase microextraction (SPME) for in vivo sampling of drugs and metabolites in the bloodstream of freely moving animals eliminates the need for blood withdrawal in order to generate pharmacokinetics (PK) profiles in support of pharmaceutical drug discovery studies. In this study, SPME was applied for in vivo sampling in mice for the first time and enables the use of a single animal to construct the entire PK profile. In vivo SPME sampling procedure used commercial prototype single-use in vivo SPME probes with a biocompatible extractive coating and a polyurethane sampling interface designed to facilitate repeated sampling from the same animal. Pre-equilibrium in vivo SPME sampling, kinetic on-fibre standardization calibration and liquid chromatography–tandem mass spectrometry analysis (LC–MS/MS) were used to determine unbound and total circulating concentrations of carbamazepine (CBZ) and its active metabolite carbamazepine-10,11-epoxide (CBZEP) in mice (n = 7) after 2 mg/kg intravenous dosing. The method was linear in the range of 1–2000 ng/mL CBZ in whole blood with acceptable accuracy (93–97%) and precision (<17% RSD). The single dose PK results obtained using in vivo SPME sampling compare well to results obtained by serial automated blood sampling as well as by the more conventional method of terminal blood collection from multiple animals/time point. In vivo SPME offers the advantages of serial and repeated sampling from the same animal, speed, improved sample clean-up, decreased animal use and the ability to obtain both free and total drug concentrations from the same experiment. 相似文献
118.
Kai-Chun Chang 《液相色谱法及相关技术杂志》2018,41(8):445-450
The bioequivalence of two Florfenicol (FF) products in pigs was evaluated. A 2?×?2 crossover trial with a 14 days wash-out period was performed. The pigs were orally administered in a single dose (2?mg/kg b.w of FF). Serum samples were analyzed using a liquid chromatography-tandem mass spectrometry method. The limit of quantification was 0.1?ng/mL, and the calibration range was 1.0–100.0?ng/mL. Furthermore, intraday and interday were 5.43–9.09% and 6.23–9.68%, respectively. The areas under the curve (AUC0–48) for the test product B of FF and reference product A were 7289.61?±?1750.44 and 6545.01?±?2766.25?h?×?ng/mL, respectively. The highest concentrations of FF in the serum (Cmax) were 726.05?±?211.77 and 641.97?±?117.94?ng/mL. The mean retention times (MRT) was 7.91?±?1.98 and 7.76?±?2.89?h while the half-lives (T1/2) were 4.07?±?1.71 and 4.99?±?3.30?h. From the analysis of variance results, the p values of Cmax and AUC0–∞ for the 90% confidence interval were 0.492 and 0.320 (p?>?0.05), respectively. A comparison between the test product and the reference product showed no significant difference. Both products showed bioequivalence after being administered in pigs. 相似文献
119.
120.
环氧合酶-2抑制剂的三维定量构效关系研究 总被引:2,自引:0,他引:2
建立三环系COX-1和COX-2抑制剂结构与活性的三维定量构效关系模型,为设 计新型的具有选择性的COX-2抑制剂提供线索。通过与酶的对接并优化,确定化合 物在受体结合腔中的构象,利用比较分子力场分析方法建立三维定量构效关系模型 。模型1R_(cv)~2=0.685,最佳主成分数为6,传统相关系数为R~2=0.988, F-726. 2,标准偏差S = 0.080;模型2 R_(cv)~2 = 0.573,最佳主成分数为6,传统相关 系数为R~2=0.996, F = 1147.6,标准偏差S = 0.034。所得的模型不仅解释了化合 物的构效关系,而且对预测集中的化合物有很好的预测能力;比较不同模型的系数 相关图,分析了结构与活性、结构与选择性的关系,得到的结果可以指导新化合物 的设计与合成。 相似文献